ONCY
Income statement / Annual
Last year (2025), Oncolytics Biotech, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Oncolytics Biotech, Inc.'s net income was -$28.76 M.
See Oncolytics Biotech, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$95.38 K
|
$90.77 K
|
$162.23 K
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$95.38 K
|
-$90.77 K
|
-$162.23 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$13.31 M
|
$15.44 M
|
$13.35 M
|
$11.37 M
|
$12.92 M
|
$12.95 M
|
$10.82 M
|
$9.42 M
|
$9.39 M
|
$9.77 M
|
| General & Administrative Expenses |
$15.41 M
|
$10.10 M
|
$11.82 M
|
$8.18 M
|
$12.86 M
|
$12.51 M
|
$0.00
|
$0.00
|
$0.00
|
$5.36 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$15.41 M
|
$10.10 M
|
$11.82 M
|
$8.18 M
|
$12.86 M
|
$12.51 M
|
$9.33 M
|
$7.24 M
|
$6.21 M
|
$5.36 M
|
| Other Expenses |
$0.00
|
$0.00
|
$303.78 K
|
$288.83 K
|
$451.95 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$162.23 K
|
| Operating Expenses |
$28.73 M
|
$25.54 M
|
$25.47 M
|
$19.84 M
|
$26.23 M
|
$25.46 M
|
$20.14 M
|
$16.66 M
|
$15.61 M
|
$15.29 M
|
| Cost And Expenses |
$28.73 M
|
$25.54 M
|
$25.47 M
|
$19.84 M
|
$26.23 M
|
$25.46 M
|
$20.14 M
|
$17.27 M
|
$15.61 M
|
$15.29 M
|
| Interest Income |
$529.64 K
|
$1.20 M
|
$1.33 M
|
$528.00 K
|
$0.00
|
$90.36 K
|
$179.28 K
|
$182.24 K
|
$127.42 K
|
$167.12 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$70.00 K
|
$87.00 K
|
$303.78 K
|
$288.83 K
|
$452.00 K
|
$89.00 K
|
$485.57 K
|
$95.38 K
|
$88.90 K
|
$162.23 K
|
| EBITDA |
-$28.66 M |
-$25.46 M |
-$25.17 M |
-$19.55 M |
-$25.78 M |
-$25.37 M |
-$19.66 M |
-$17.18 M |
-$15.26 M |
-$13.80 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$45.00 K
|
$2.84 M
|
$4.63 M
|
$1.60 M
|
-$20.06 K
|
$2.95 M
|
-$12.98 M
|
$173.50 K
|
$130.10 K
|
$163.90 K
|
| Income Before Tax |
-$28.68 M
|
-$22.70 M
|
-$20.85 M
|
-$18.24 M
|
-$26.26 M
|
-$22.51 M
|
-$33.12 M
|
-$16.49 M
|
-$15.48 M
|
-$15.13 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$79.00 K
|
$95.00 K
|
$73.12 K
|
$61.89 K
|
$49.00 K
|
$0.00
|
$0.00
|
$548.04 K
|
$141.50 K
|
$9.37 K
|
| Net Income |
-$28.76 M
|
-$22.79 M
|
-$20.92 M
|
-$18.30 M
|
-$26.30 M
|
-$22.51 M
|
-$45.55 M
|
-$17.04 M
|
-$15.62 M
|
-$15.14 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.41 |
-0.3 |
-0.41 |
-0.44 |
-0.49 |
-0.48 |
-1.5 |
-1.06 |
-1.12 |
-1.2 |
| EPS Diluted |
-0.41 |
-0.3 |
-0.41 |
-0.44 |
-0.49 |
-0.48 |
-1.5 |
-1.06 |
-1.12 |
-1.2 |
| Weighted Average Shares Out |
$95.86 M
|
$76.48 M
|
$67.62 M
|
$58.03 M
|
$53.51 M
|
$40.34 M
|
$22.14 M
|
$16.02 M
|
$13.94 M
|
$12.62 M
|
| Weighted Average Shares Out Diluted |
$95.86 M
|
$76.48 M
|
$67.62 M
|
$58.03 M
|
$53.51 M
|
$40.34 M
|
$22.14 M
|
$16.02 M
|
$13.94 M
|
$12.62 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
